Medical device companies love being first out of the chute with a new technology, but sometimes it is better to ride into the arena with a second-generation product designed to overcome the limitations seen with those first-to-market devices.

To say someone has floated a policy proposal in Washington is akin to saying the traffic in the DC area was bad yesterday. It happens every day, so who cares? Here are three policy proposals that emerged over the past year (or three), proposals that have either slipped beneath the waves or are struggling to stay afloat. FDA’s clinical trial disclosure proposal: Dead duck The idea that FDA would just up and disclose the results of clinical trials has been bouncing around...